Subscription Required

Only paid subscribers to Radar on Specialty Pharmacy can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Radar on Specialty Pharmacy receive

  • 12 monthly issues packed with strategic information on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
February 2018

Recent Stories

From Radar on Specialty Pharmacy - More than a year after legislation resulted in a reimbursement gap for home infusion providers of Part B infusible drugs furnished through durable medical equipment (DME), relief is finally in sight after President Trump signed the Bipartisan Budget Act of 2018 on Feb. 9. The recently signed budget established a transitional payment that kicks in Jan. Read more

In an effort to make sure cancer patients receive comprehensive care after… Read more

When the FDA approved the third gene therapy ever last month, a… Read more

An earlier version of this story incorrectly said that the FDA approved… Read more

From the Editor

Welcome to Your Radar on Specialty Pharmacy Subscriber Website

Exclusively for subscribers to Radar on Specialty Pharmacy (formerly Specialty Pharmacy News), this website is your source for PDFs of back issues, archives of articles and data, and more!

Please e-mail me with comments on the latest issue, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 10, 2018
Specialty Pharmacy News is about to become Radar on Specialty Pharmacy

With the February issue of SPN, we will adopt a new publication name: Radar on Specialty Pharmacy. While our focus is still squarely on providing strategies and analysis for managing high-cost specialty products, our new name signals a renewed commitment to in-depth, forward-looking coverage. Every issue will bring incisive coverage of the companies, people, catalysts and trends that shape the pharma industry today and in the future.

Radar on Specialty Pharmacy will join our other newly named publications: Radar on Medicare Advantage (formerly Medicare Advantage News) and Radar on Drug Benefits (formerly Drug Benefit News), available alongside Health Plan Weekly and Health Business Daily. Visit the AISHealth Marketplace for more information about our publications.

November 16, 2017
FDA Begins Implementing Naming Guidance

The FDA has started adding 4-letter suffixes to non-biosimilar biologics per its January final guidance: Mepsevii (vestronidase alfa-vjbk) and Hemlibra (emicizumab-kxwh)

August 30, 2017
First Gene Therapy Gets FDA Approval

FDA approves first gene therapy in U.S., Novartis’ CAR-T drug Kymriah, for treatment of people up to 25 years old with B-cell precursor acute lymphoblastic leukemia that is refractory or has relapsed at least twice http://tinyurl.com/y8xku8ol

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?